Indeed, aromatase inhibitors in combination with PI3K inhibitors are currently undergoing clinical trials in order to overcome refractoriness to standard anti-tumoral therapies in estrogen receptor-positive (luminal) breast cancers [36]. This evidence concerns the gene CYP19A1 and breast carcinoma.